Live updates

Cancer drug's price makes it 'impossible' to support

The National Institute for Health and Care Excellence (Nice) has spoken of their 'disappointment' at not being able to recommend a breast cancer drug which can extend the life of terminal patients for up to 6 months.

Even with the extra flexibility that we can apply to cancer drugs, the price that Roche, the manufacturer are charging, makes it impossible to make that positive recommendation to the NHS.

– Andrew Dillon, Chief Executive of Nice

Terminal cancer sufferer condemns withdrawal of drug

A terminal cancer sufferer from Derbyshire has condemned the decision by the NHS drugs watchdog to withdraw the use of the drug Kadcyla to fight the disease on the grounds of cost.

The drug, which can add months to the life of women dying of breast cancer, costs £90,000 for a course of treatment.

The National Institute for Health and Care Excellence (Nice) said the drug was too expensive to recommend for widespread use in the health service.

Hayley Kalinins, from Borrowash, said: "How can they put a price on anybody's life?

"They do need to bring the cost of the drug down - that is obvious to everybody.

"It's been the miracle drug (for me). I've undergone four different types of chemotherapy before starting this drug.

"I've been on this drug for 18 weeks and experienced very minimal side effects from it, enabling me to have good family times with the four children."

Advertisement

National

Breast cancer drug decision 'an injustice'

The manufacturer of a breast cancer drug which has been deemed "too expensive" to be offered by the NHS has hit back at the decision.

Dr Jayson Dallas, general manager of Roche Products Limited, declared it "an incredible injustice."

Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.

Refusing patients access to this drug is an incredible injustice and tantamount to turning the clock back in cancer research and development. We plan to appeal this decision.

– Dr Jayson Dallas
National

Breast cancer drug manufacturer 'could have done more'

The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.

Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:

Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.

We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.

– Sir Andrew Dillon
National

NHS won't offer 'last hope' breast cancer drug

NHS
The NHS financial watchdog, Nice, has decided Kadcyla is too expensive. Credit: PA

The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.

Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.

However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.

The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.

Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.

Advertisement

Breast cancer survivors meet in Birmingham

Women who have survived breast cancer in the last year Credit: Sue Matthews

A group of women who all started chemotherapy for breast cancer a year ago are meeting up in Birmingham this weekend. They were introduced via the Breast Cancer Care website for patients.

They told ITV News Central they've created their own support network and have spoken to eachother throughout their treatment. A number of the group are from the Midlands.

Police launch breast surgeon investigation, full report

West Midlands Police have launched an investigation into a surgeon who allegedly carried out botched or unnecessary breast cancer operations at three hospitals in the West Midlands. It follows a referral from the General Medical Council, which has already suspended Ian Paterson.

Yesterday Central Tonight reported that hundreds of women who claim they had breast surgery they did not need, are calling for him to be struck off. The operations were carried out between 1994 and May last year both on the NHS and privately.

Load more updates

Advertisement

Today's top stories